t
| Date | 6 May 2022 |
| Time | 15:08:44 |
| Category | Director/PDMR dealings |
| ID | 6638K |
GENERAL TEXT AMENDMENT
The following amendments have been made to the 'Director/ PDMR Shareholding' announcement released on 5th May 2022 at 11:10am under RNS No 4714K:
|
1. Amendment to 4(c) Nature of Transaction: The initial Notice incorrectly described the nature of the transaction as an exercise of Performance Rights granted under an Employee Share Scheme, when in fact the securities were purchased by the director "on market" through a broker. 2. Amendment to 4(d) Currency: The consideration currency was incorrectly disclosed as AUD, when the consideration paid was in fact GBP. |
All other details remain unchanged.
The full amended text is shown below.
MGC Pharmaceuticals Ltd.
PDMR Notifications
06 May 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, wishes to advise that this "amending" notice has been issued to correct 2 errors on the "initial" notice lodged on 5 May 2022 in relation to the recent purchase of MGC shares on the LSE by Dr Stephen Parker, a non-executive director of the Company.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated
|
||||
|
(a) |
Name |
Dr Stephen Barry Parker |
|||
|
2 |
Reason for the notification
|
||||
|
(a) |
Position
|
Director |
|||
|
(b) |
Initial notification/amendment
|
amendment |
|||
|
(c) |
If amendment: reason
|
This amending notice has been issued to correct the following errors on the Initial Notice released on 5 May 2022. 3. Amendment to 4(c) Nature of Transaction: The initial Notice incorrectly described the nature of the transaction as an exercise of Performance Rights granted under an Employee Share Scheme, when in fact the securities were purchased by the director "on market" through a broker. 4. Amendment to 4(d) Currency: The consideration currency was incorrectly disclosed as AUD, when the consideration paid was in fact GBP. |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
|
Full name of entity |
MGC Pharmaceuticals Limited
|
|||
|
|
Legal Entity Identifier Code |
213800HRE3FQJ6RK4H10
|
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
|
||||
|
(a) |
Description of the financial instrument, type of instrument |
Fully Paid Ordinary Shares (DI) |
|||
|
(b) |
Identification Code (ISIN)
|
AU000000MXC6 |
|||
|
(c) |
Nature of transaction |
On market purchase |
|||
|
(d) |
Currency |
Price |
Volume |
Total |
|
|
|
GBP |
£0.0135 |
1,111,111 |
£15,012 |
|
|
|
Aggregated information |
||||
|
|
GBP |
£0.0135 |
1,111,111 |
£15,012 |
|
|
(e) |
Date of transaction
|
2022-05-04 |
|||
|
(f) |
Place of transaction
|
London Stock Exchange |
|||
--Ends--
Authorised for release by the Company Secretary, for further information please contact:
|
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 |
MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 |
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma